65 related articles for article (PubMed ID: 22563106)
1. Histone deacetylase inhibition modulates E-cadherin expression and suppresses migration and invasion of anaplastic thyroid cancer cells.
Catalano MG; Fortunati N; Pugliese M; Marano F; Ortoleva L; Poli R; Asioli S; Bandino A; Palestini N; Grange C; Bussolati B; Boccuzzi G
J Clin Endocrinol Metab; 2012 Jul; 97(7):E1150-9. PubMed ID: 22563106
[TBL] [Abstract][Full Text] [Related]
2. Antiproliferative Effects of Epigenetic Modifier Drugs Through E-cadherin Up-regulation in Liver Cancer Cell Lines.
Uribe D; Cardona A; Esposti DD; Cros MP; Cuenin C; Herceg Z; Camargo M; Cortés-Mancera FM
Ann Hepatol; 2018; 17(3):444-460. PubMed ID: 29735783
[TBL] [Abstract][Full Text] [Related]
3. Investigation into the use of histone deacetylase inhibitor MS-275 as a topical agent for the prevention and treatment of cutaneous squamous cell carcinoma in an SKH-1 hairless mouse model.
Kalin JH; Eroglu A; Liu H; Holtzclaw WD; Leigh I; Proby CM; Fahey JW; Cole PA; Dinkova-Kostova AT
PLoS One; 2019; 14(3):e0213095. PubMed ID: 30865688
[TBL] [Abstract][Full Text] [Related]
4. TIMP-2 modulates cancer cell transcriptional profile and enhances E-cadherin/beta-catenin complex expression in A549 lung cancer cells.
Bourboulia D; Han H; Jensen-Taubman S; Gavil N; Isaac B; Wei B; Neckers L; Stetler-Stevenson WG
Oncotarget; 2013 Jan; 4(1):166-76. PubMed ID: 23371049
[TBL] [Abstract][Full Text] [Related]
5. N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression.
Nieman MT; Prudoff RS; Johnson KR; Wheelock MJ
J Cell Biol; 1999 Nov; 147(3):631-44. PubMed ID: 10545506
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic regulation of intestinal peptide transporter PEPT1 as a potential strategy for colorectal cancer sensitization.
Wang Y; Wang J; Yang L; Qiu L; Hua Y; Wu S; Zeng S; Yu L; Zheng X
Cell Death Dis; 2021 May; 12(6):532. PubMed ID: 34031358
[TBL] [Abstract][Full Text] [Related]
7. dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe.
Rodrigues JS; Chenlo M; Bravo SB; Perez-Romero S; Suarez-Fariña M; Sobrino T; Sanz-Pamplona R; González-Prieto R; Blanco Freire MN; Nogueiras R; López M; Fugazzola L; Cameselle-Teijeiro JM; Alvarez CV
Nat Commun; 2024 May; 15(1):3736. PubMed ID: 38744818
[TBL] [Abstract][Full Text] [Related]
8. Establishment of an ovarian metastasis model and possible involvement of E-cadherin down-regulation in the metastasis.
Kuwabara Y; Yamada T; Yamazaki K; Du WL; Banno K; Aoki D; Sakamoto M
Cancer Sci; 2008 Oct; 99(10):1933-9. PubMed ID: 19016752
[TBL] [Abstract][Full Text] [Related]
9. New Treatment Strategy Targeting Galectin-1 against Thyroid Cancer.
Gheysen L; Soumoy L; Trelcat A; Verset L; Journe F; Saussez S
Cells; 2021 May; 10(5):. PubMed ID: 34063063
[TBL] [Abstract][Full Text] [Related]
10. Expression of E-Cadherin/Beta-Catenin in Epithelial Carcinomas of the Thyroid Gland.
Ivanova K; Ananiev J; Aleksandrova E; Ignatova MM; Gulubova M
Open Access Maced J Med Sci; 2017 Apr; 5(2):155-159. PubMed ID: 28507620
[TBL] [Abstract][Full Text] [Related]
11. Chromosomal protein HMGN1 modulates the expression of N-cadherin.
Rubinstein YR; Furusawa T; Lim JH; Postnikov YV; West KL; Birger Y; Lee S; Nguyen P; Trepel JB; Bustin M
FEBS J; 2005 Nov; 272(22):5853-63. PubMed ID: 16279949
[TBL] [Abstract][Full Text] [Related]
12. Integrated analysis of transcriptome data revealed MMP3 and MMP13 as critical genes in anaplastic thyroid cancer progression.
J Cell Physiol; 2024 Apr; ():. PubMed ID: 38567739
[No Abstract] [Full Text] [Related]
13. Combination of Novel Therapies and New Attempts in Anaplastic Thyroid Cancer.
Li W; Li Y; Li J; Pang H
Technol Cancer Res Treat; 2023; 22():15330338231169870. PubMed ID: 37122242
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic Targets and Their Inhibitors in Thyroid Cancer Treatment.
Zhang K; Wang J; He Z; Qiu X; Sa R; Chen L
Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111316
[TBL] [Abstract][Full Text] [Related]
15. Selective inhibition of HDAC6 promotes bladder cancer radiosensitization and mitigates the radiation-induced CXCL1 signalling.
Tsai YC; Wang TY; Hsu CL; Lin WC; Chen JY; Li JH; Pu YS; Cheng AL; Cheng JC; Su SF
Br J Cancer; 2023 May; 128(9):1753-1764. PubMed ID: 36810912
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitor, panobinostat, exerts anti-proliferative effect with partial normalization from aberrant epigenetic states on granulosa cell tumor cell lines.
Hazama Y; Tsujioka T; Kitanaka A; Tohyama K; Shimoya K
PLoS One; 2022; 17(7):e0271245. PubMed ID: 35802681
[TBL] [Abstract][Full Text] [Related]
17. Tunicamycin as a Novel Redifferentiation Agent in Radioiodine Therapy for Anaplastic Thyroid Cancer.
Choi YJ; Lee JE; Ji HD; Lee BR; Lee SB; Kim KS; Lee IK; Chin J; Cho SJ; Lee J; Lee SW; Ha JH; Jeon YH
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33499100
[TBL] [Abstract][Full Text] [Related]
18. Loss of MADD expression inhibits cellular growth and metastasis in anaplastic thyroid cancer.
Saini S; Sripada L; Tulla K; Kumar P; Yue F; Kunda N; Maker AV; Prabhakar BS
Cell Death Dis; 2019 Feb; 10(2):145. PubMed ID: 30760700
[TBL] [Abstract][Full Text] [Related]
19. Resveratrol Suppresses the Growth and Enhances Retinoic Acid Sensitivity of Anaplastic Thyroid Cancer Cells.
Li YT; Tian XT; Wu ML; Zheng X; Kong QY; Cheng XX; Zhu GW; Liu J; Li H
Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29596381
[TBL] [Abstract][Full Text] [Related]
20. Effect of Slug-Mediated Down-Regulation of E-Cadherin on Invasiveness and Metastasis of Anaplastic Thyroid Cancer Cells.
Sheng L; Zhang S; Xu H
Med Sci Monit; 2017 Jan; 23():138-143. PubMed ID: 28070118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
